✦ LIBER ✦

Two Doses of Daclizumab With Delayed Introduction of Low-Dose Tacrolimus in Elderly Recipients of Cadaveric Renal Transplants From Donors >55 Years of Age

✍ Scribed by A. Osuna; M.A. Gentil; L. Capdevila; C. Cantarell; A. Mazuecos; P. Pereira; G. Rodrı́guez-Algarra; M. González-Molina

Book ID: 116931042
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 62 KB
Volume: 37
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2005.02.039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of delayed introduct

Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age

✍ M.A Gentil; A Osuna; L Capdevila; G Rodriguez-Algarra; C Cantarell; P Pereira; M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Evaluation of renal function in liver tr

Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial

✍ Eric M. Yoshida; Paul J. Marotta; Paul D. Greig; Norman M. Kneteman; Denis Marle 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Posttransplant chronic renal failure, secondary to calcineurin inhibitor agents, is emerging as a major problem in liver transplantation. We report a randomized clinical trial comparing daclizumab, delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6), Investigational Arm (n